Developments in virology have led to the development of several classes of therapeutics, including treatments or prevention of microbial infection and gene therapy. Gene therapy holds the promise of therapeutic options for a variety of diseases. A key issue in gene therapy is the development of gene delivery vehicles that evade immune or inflammatory response, are non-toxic, and target the gene effectively. To fulfill the national need for these types of therapeutic options, the UCLA Virology and Gene Therapy Training Program aims to provide a unique and outstanding environment for predoctoral and postdoctoral trainees pursuing research careers in fields related to gene therapy. This program will establish a solid training in fundamental virology and its applications in gene therapy. The research interests of our faculty encompass viral entry, viral gene expression regulation, replication of viral genome, cell biology during viral infection, viral particle assembly, viral carcinogenesis and viral immunology, as well as designing novel vectors and tracking viral vectors in vivo. With strong basic research programs on retroviruses, adenoviruses, SV40, hepatitis C, poliovirus, influenza virus and herpesviruses, our faculty has been and will be continuously developing viral vectors from these viruses and monitoring gene expression in vivo using non-invasive imaging technologies in combination stem cell biology. The trainees will be exposed to clinical and diagnostic issues during their training to underscore the therapeutic applications of their research projects, and be encouraged to form translational collaborations with basic and clinical mentors. This bridge in training environment will enhance the translation from basic science to clinical application in gene and cellular therapy. The training program constitutes 1) original research work with one or more of our faculty;2) formal course work which provides comprehensive background on virology and gene therapy;and 3) regular research conferences and seminars, presented by invited guest speakers, faculty members and trainees;4) training in best practices in research, responsible conduct and career development. The training committee will select trainees via a competitive process. Appointments are renewable with satisfactory progress (up to 2 years predoctoral, 1 year postdoctoral). The training program is fully integrated with the reorganized PhD programs in biosciences at UCLA. The progress of the trainees and the program are reviewed periodically. At UCLA, this rigorous training program with emphasis on vertical integration of basic sciences and therapeutic applications produces the scientists required for long-term development of virology and gene therapy.

Public Health Relevance

Viruses cause a variety of diseases but their natural ability to deliver genetic materials into cells can be utilized to reprogram cells against inherited diseases, cancer, AIDS, and immune disorders. This training program is designed to produce future scientists in the fields of virology and gene therapy that will be able to develop antiviral drugs and vaccines, to design new, more effective viral vectors, understand how to apply these vectors to human diseases, and ensure that new therapies are available in the future.

National Institute of Health (NIH)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Microbiology and Infectious Diseases Research Committee (MID)
Program Officer
Robbins, Christiane M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
Park, Arnold; Won, Sohui T; Pentecost, Mickey et al. (2014) CRISPR/Cas9 allows efficient and complete knock-in of a destabilization domain-tagged essential protein in a human cell line, allowing rapid knockdown of protein function. PLoS One 9:e95101
Osokine, Ivan; Snell, Laura M; Cunningham, Cameron R et al. (2014) Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection. Proc Natl Acad Sci U S A 111:7409-14
Lin, Amy H; Timberlake, Nina; Logg, Christopher R et al. (2014) MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response. Hum Gene Ther 25:759-71
Wilson, Elizabeth B; Yamada, Douglas H; Elsaesser, Heidi et al. (2013) Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340:202-7
Nixon, Christopher C; Vatakis, Dimitrios N; Reichelderfer, Scott N et al. (2013) HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 122:2195-204
Snyder, Jonathan E; Azizgolshani, Odisse; Wu, Bingbing et al. (2011) Rescue of infectious particles from preassembled alphavirus nucleocapsid cores. J Virol 85:5773-81
Ho, Ritchie; Chronis, Constantinos; Plath, Kathrin (2011) Mechanistic insights into reprogramming to induced pluripotency. J Cell Physiol 226:868-78
Roos, W H; Gibbons, M M; Arkhipov, A et al. (2010) Squeezing protein shells: how continuum elastic models, molecular dynamics simulations, and experiments coalesce at the nanoscale. Biophys J 99:1175-81
Johnston, Samantha H; Lobritz, Michael A; Nguyen, Sandra et al. (2009) A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol 83:11016-26
Hwang, Seungmin; Kim, Kyeong Seon; Flano, Emilio et al. (2009) Conserved herpesviral kinase promotes viral persistence by inhibiting the IRF-3-mediated type I interferon response. Cell Host Microbe 5:166-78

Showing the most recent 10 out of 14 publications